Chemotherapy & Immunosuppressive Pharmacology

S-phase antimetabolites mimic endogenous purines, pyrimidines, or folate cofactors to halt DNA replication. Methotrexate (MTX) competitively inhibits dihydrofolate reductase (DHFR), depleting tetrahydrofolate cofactors required by thymidylate synthase and de novo purine synthesis; it treats leukemias/lymphomas, osteosarcoma, ectopic pregnancy, rheumatoid arthritis, and psoriasis, and causes myelosuppression (rescued by leucovorin [folinic acid, N⁵-formyl-THF]), mucositis, hepatotoxicity/hepatic fibrosis, pulmonary fibrosis, and crystalline nephrotoxicity. 5-Fluorouracil (5-FU) (and its oral prodrug capecitabine) is converted into 5-FdUMP, which forms a covalent ternary complex with folate and thymidylate synthase to block dUMP→dTMP conversion (producing "thymine-less death"; leucovorin is co-administered with 5-FU in colorectal cancer NOT as a rescue agent, but to stabilize the 5-FdUMP-thymidylate synthase complex and potentiate cytotoxicity; patients with dihydropyrimidine dehydrogenase [DPD] deficiency suffer fatal 5-FU toxicity). Cytarabine (Ara-C) inhibits DNA polymerase in AML and causes high-dose cerebellar ataxia/dysarthria and pancytosic megaloblastosis. In M-phase, vinca alkaloids (vincristine, vinblastine) bind β-tubulin to prevent microtubule polymerization (vincristine causes dose-limiting sensorimotor stocking-glove peripheral neuropathy and paralytic ileus, while vinblastine "blasts" the bone marrow), whereas taxanes (paclitaxel, docetaxel) hyperstabilize polymerized microtubules (preventing mitotic spindle disassembly).

Cell-cycle non-specific cytotoxic agents directly cross-link or cleave DNA strands. Cyclophosphamide and ifosfamide are nitrogen mustard prodrugs bioactivated by hepatic CYP2B6/3A4 into cytotoxic phosphoramide mustard and the urotoxic metabolite acrolein, which sloughs transitional urothelium to cause hemorrhagic cystitis and bladder cancer—prevented by vigorous hydration and mesna (a sulfhydryl compound that binds and inactivates acrolein directly within the acidic urine). Nitrosoureas (carmustine, lomustine, temozolomide) are highly lipophilic alkylators that cross the blood-brain barrier to treat glioblastoma multiforme. Platinum analogs cause distinct organ toxicities recalled via "Cisplatin = Acoustic/Kidney, Carboplatin = Marrow, Oxaliplatin = Neuropathy": cisplatin causes severe proximal tubular nephrotoxicity (prevented with saline diuresis and amifostine, a free-radical thiol scavenger) and high-frequency cochlear ototoxicity; oxaliplatin causes acute cold-triggered laryngopharyngeal dysesthesia and peripheral neuropathy. Anthracyclines (doxorubicin, daunorubicin) intercalate DNA, inhibit topoisomerase II, and generate iron-mediated reactive oxygen species that cause irreversible, cumulative dose-dependent dilated cardiomyopathy—prevented by the intracellular iron chelator dexrazoxane. Bleomycin chelates iron to generate free radicals that cleave DNA in G₂ phase (used in Hodgkin ABVD and testicular BEP regimens) and causes pulmonary fibrosis and flagellate skin hyperpigmentation because lung and skin lack bleomycin hydrolase (with minimal myelosuppression).

Both calcineurin inhibitors and mTOR inhibitors bind cytosolic immunophilins, but they act on completely different stages of the T-cell activation cascade and exhibit distinct organ toxicities. Cyclosporine binds cyclophilin, whereas tacrolimus (FK506) binds FK506-binding protein 12 (FKBP12); both drug-immunophilin complexes inhibit the calcium/calmodulin-dependent phosphatase calcineurin, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T-cells) and halting IL-2 gene transcription (Signal 1 blockade). Both calcineurin inhibitors share dose-limiting afferent arteriolar vasoconstrictive nephrotoxicity (acute and chronic interstitial fibrosis), hypertension, hyperkalemia, hypomagnesemia, and neurotoxicity (tremor, posterior reversible encephalopathy syndrome [PRES]). However, their cosmetic and metabolic side effects diverge: cyclosporine uniquely causes gingival hyperplasia and hirsutism, whereas tacrolimus causes significantly higher rates of post-transplant diabetes mellitus (pancreatic β-cell toxicity) and alopecia. Conversely, sirolimus (rapamycin) and everolimus also bind FKBP12, but the sirolimus-FKBP12 complex inhibits mTOR (mechanistic target of rapamycin)—blocking IL-2 receptor downstream signaling (Signal 3) and arresting T- and B-cells in the G₁→S transition. Because mTOR inhibitors are non-nephrotoxic, they serve as renal-sparing alternatives to calcineurin inhibitors (and coat drug-eluting coronary stents to prevent intimal smooth muscle proliferation), but cause severe hyperlipidemia/hypertriglyceridemia, thrombocytopenia/leukopenia, impaired wound healing, and interstitial pneumonitis.

Proliferating T- and B-lymphocytes depend exclusively on the de novo purine synthesis pathway (unlike other mammalian cells, which can utilize the HGPRT purine salvage pathway). Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium are prodrugs of mycophenolic acid, which reversibly and non-competitively inhibits inosine monophosphate dehydrogenase (IMPDH)—the rate-limiting enzyme converting IMP to GMP—selectively starving lymphocytes of guanosine nucleotides. MMF has largely replaced azathioprine in solid organ transplant triple therapy (paired with tacrolimus and prednisone) and lupus nephritis; its major toxicities are dose-limiting gastrointestinal diarrhea/vomiting, leukopenia, CMV reactivation, and severe first-trimester teratogenicity (congenital microtia/cleft lip; must be switched to azathioprine prior to pregnancy). Azathioprine is a prodrug cleaved non-enzymatically to 6-mercaptopurine (6-MP), which is converted by HGPRT into cytotoxic 6-thioguanine nucleotides that block de novo purine synthesis. Because 6-MP is inactivated by both thiopurine methyltransferase (TPMT) and xanthine oxidase (XO), patients with genetic TPMT deficiency or those co-prescribed allopurinol or febuxostat (XO inhibitors) develop fatal pancytopenia. Biologic transplant agents include basiliximab (a chimeric monoclonal antibody against the IL-2Rα chain [CD25] used for induction) and belatacept (a high-affinity CTLA-4-Ig fusion protein blocking CD80/86 Signal 2 costimulation; contraindicated in EBV-seronegative recipients due to post-transplant lymphoproliferative disorder [PTLD]).

Licensing examinations repeatedly test the exact biochemical pairing of cytotoxic chemotherapeutics with their tissue-selective rescue agents: (1) High-Dose Methotrexate + Leucovorin (Folinic Acid): leucovorin (N⁵-formyl-tetrahydrofolate) bypasses blocked dihydrofolate reductase to replenish reduced folate pools in normal bone marrow and gastrointestinal mucosa (coupled with IV sodium bicarbonate urinary alkalinization and glucarpidase—recombinant bacterial carboxypeptidase G₂ that enzymatically cleaves circulating methotrexate—if acute renal failure occurs); (2) Cyclophosphamide / Ifosfamide + Mesna: mesna (2-mercaptoethane sulfonate) contains a reactive sulfhydryl group that conjugates and detoxifies urotoxic acrolein inside the urinary bladder to prevent hemorrhagic cystitis; (3) Doxorubicin / Daunorubicin + Dexrazoxane: dexrazoxane chelates intracellular myocardial Fe³⁺, preventing anthracycline-iron free radical formation and dilated cardiomyopathy; (4) Cisplatin + Amifostine: amifostine is dephosphorylated by alkaline phosphatase on normal renal proximal tubular endothelium into an active free-radical scavenging thiol (WR-1065) that prevents nephrotoxicity; and (5) 5-Fluorouracil / Capecitabine Overdose + Uridine Triacetate: replenishes intracellular uridine pools to rescue patients with DPD deficiency or accidental 5-FU overdose. Additionally, induction chemotherapy for high-grade lymphomas (Burkitt) or acute leukemias triggers Tumor Lysis Syndrome (TLS: hyperkalemia, hyperphosphatemia, secondary hypocalcemia, and acute uric acid crystal nephropathy)—prevented with aggressive IV hydration plus allopurinol (prophylaxis) or rasburicase (recombinant urate oxidase that oxidizes existing uric acid into water-soluble allantoin; contraindicated in G6PD deficiency because the reaction generates H₂O₂).

Precision oncology matches somatic driver mutations to small-molecule kinase inhibitors (-ibs) or monoclonal antibodies (-mabs). In chronic myeloid leukemia (CML, t(9;22) Philadelphia chromosome), imatinib, dasatinib, and nilotinib competitively block the ATP-binding pocket of the constitutively active BCR-ABL fusion tyrosine kinase (and c-KIT in gastrointestinal stromal tumors [GIST]; imatinib causes periorbital/ankle fluid retention, and T315I gatekeeper mutations require ponatinib). In HER2/neu (ErbB2)-amplified breast and gastric cancers, trastuzumab (a humanized monoclonal antibody against the extracellular domain of HER2) causes reversible myocardial stunning and systolic heart failure (unlike anthracyclines, trastuzumab cardiotoxicity is not cumulative-dose-dependent and often recovers upon withdrawal, but baseline and serial echocardiograms are mandatory). In metastatic melanoma with BRAF V600E mutations, vemurafenib or dabrafenib (BRAF inhibitors) must be combined with trametinib or cobimetinib (MEK inhibitors) to prevent paradoxical RAS-driven cutaneous squamous cell carcinomas. In B-cell malignancies, rituximab targets CD20 (carrying a boxed warning for Hepatitis B virus reactivation and PML), ibrutinib inhibits Bruton tyrosine kinase (BTK) (causing atrial fibrillation and platelet bleeding), and venetoclax inhibits anti-apoptotic BCL-2. Finally, immune checkpoint inhibitors—ipilimumab (anti-CTLA-4), pembrolizumab/nivolumab (anti-PD-1), and atezolizumab/durvalumab (anti-PD-L1)—release the brakes on cytotoxic CD8⁺ T-cells, causing autoimmune immune-related adverse events (irAEs: hypophysitis, thyroiditis, colitis, pneumonitis, myocarditis) treated with systemic corticosteroids.

Transplant rejection syndromes are classified by tempo, histopathology, and immunologic effector mechanism, each dictating a specific pharmacologic intervention. Hyperacute rejection occurs within minutes to hours of vascular anastomosis when pre-existing recipient IgG antibodies (against ABO blood group antigens or donor HLA class I antigens from prior pregnancy, blood transfusions, or transplants) bind donor capillary endothelium, fixing complement (C4d) and triggering widespread fibrin-platelet thrombosis and ischemic cortical necrosis; it is irreversible (requires immediate graft nephrectomy) and is prevented prior to surgery by a negative complement-dependent cytotoxicity crossmatch. Acute rejection occurs within weeks to 6 months (or later if immunosuppression is non-adherent) via two mechanisms: Acute cellular rejection is mediated by recipient CD8⁺ cytotoxic and CD4⁺ Th1 T-lymphocytes infiltrating renal tubules (tubulitis) and arterial intima (endotheliitis), treated first-line with high-dose IV methylprednisolone pulses and T-cell-depleting anti-thymocyte globulin (ATG) if steroid-resistant; Acute antibody-mediated (humoral) rejection is driven by de novo donor-specific antibodies (DSAs) with peritubular capillary C4d deposition, treated with plasmapheresis, IVIG, and rituximab (or eculizumab [anti-C5]). Chronic rejection evolves over months to years as concentric arteriosclerosis (vascular smooth muscle intimal proliferation), interstitial fibrosis, tubular atrophy, or bronchiolitis obliterans (in lung transplants) and is largely irreversible.

Monoclonal antibodies and recombinant fusion proteins targeting specific interleukins and adhesion molecules require precise pathway matching. In plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, the Th17 axis is targeted by ustekinumab (blocks the shared p40 subunit of IL-12 and IL-23), guselkumab and risankizumab (selectively block the p19 subunit of IL-23), and secukinumab and ixekizumab (directly neutralize IL-17A; note that IL-17 inhibitors can exacerbate inflammatory bowel disease and predispose to mucocutaneous candidiasis). In atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyposis, dupilumab blocks the IL-4 receptor α-subunit (IL-4Rα), simultaneously inhibiting both IL-4 and IL-13 Th2 signaling and IgE class switching (common side effect: conjunctivitis). In severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), mepolizumab and reslizumab neutralize IL-5, while benralizumab binds the IL-5Rα receptor to induce NK-cell antibody-dependent cellular cytotoxicity (ADCC) of eosinophils. In giant cell arteritis, rheumatoid arthritis, and CAR-T-induced cytokine release syndrome (CRS), tocilizumab and sarilumab block soluble and membrane-bound IL-6 receptors (suppressing hepatic CRP/hepcidin synthesis). Finally, in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), eculizumab and ravulizumab bind complement C5 to prevent cleavage into C5a and C5b-9 membrane attack complex—mandating meningococcal (MenACWY + MenB) vaccination at least 2 weeks prior to prevent fulminant Neisseria meningitidis sepsis.

HER2/neu (ErbB2) Overexpression (breast and gastroesophageal adenocarcinoma) is targeted by trastuzumab and pertuzumab (extracellular monoclonal antibodies) or lapatinib / tucatinib (intracellular tyrosine kinase inhibitors). Unlike anthracyclines, which cause dose-dependent, irreversible myocyte necrosis (prevented by iron chelator dexrazoxane), trastuzumab causes dose-independent, typically reversible myocardial stunning (discontinue if LVEF drops significantly). EGFR (ErbB1) is targeted by monoclonal antibodies (cetuximab, panitumumab—used in KRAS/NRAS wild-type metastatic colorectal cancer and head/neck SCC; if KRAS is mutated downstream, blocking upstream EGFR is futile!) or small-molecule EGFR TKIs (osimertinib, erlotinib, gefitinib—used in EGFR exon 19 deletion or L858R/T790M mutant non-small cell lung cancer; signature toxicity is a papulopustular acneiform rash that correlates with clinical tumor response, plus interstitial lung disease). VEGF-A is neutralized by bevacizumab (or VEGF receptor TKIs sunitinib, sorafenib, pazopanib, lenvatinib in renal cell and hepatocellular carcinoma), inhibiting tumor angiogenesis but causing hypertension, proteinuria, arterial thromboembolism, impaired wound healing, and gastrointestinal perforation.

BCR-ABL1 Tyrosine Kinase Inhibitors (imatinib, dasatinib, nilotinib, ponatinib) competitively bind the ATP-binding pocket of the constitutively active Philadelphia chromosome t(9;22) fusion kinase in Chronic Myeloid Leukemia (CML) and Ph+ ALL, and also inhibit c-KIT (CD117) in Gastrointestinal Stromal Tumors (GIST). Signature imatinib toxicity is periorbital and lower-extremity fluid retention/edema and myalgias; resistance via the T315I "gatekeeper" mutation requires ponatinib. In BRAF V600E-mutant melanoma, BRAF inhibitors (vemurafenib, dabrafenib) are always combined with downstream MEK inhibitors (trametinib, cobimetinib) to prevent paradoxical MAPK activation and cutaneous squamous cell carcinomas/keratoacanthomas. In hematologic malignancies, rituximab targets CD20 (B-cell NHL, CLL, ITP, RA, GPA/MPA), ibrutinib / acalabrutinib inhibit Bruton Tyrosine Kinase (BTK) in CLL/mantle cell lymphoma (causing atrial fibrillation and platelet dysfunction/bleeding), venetoclax inhibits anti-apoptotic BCL-2 in CLL/AML (causing rapid Tumor Lysis Syndrome), bortezomib / carfilzomib inhibit the 26S proteasome in multiple myeloma (causing painful peripheral neuropathy and herpes zoster reactivation—requires acyclovir prophylaxis), and PARP inhibitors (olaparib, niraparib) exploit synthetic lethality in BRCA1/BRCA2-mutated ovarian, breast, prostate, and pancreatic cancers by blocking base-excision single-strand DNA repair when homologous recombination is already defective.

Tumor cells evade cytotoxic CD8⁺ T-lymphocytes by expressing Programmed Death-Ligand 1 (PD-L1), which engages PD-1 on T cells to induce anergy/exhaustion, while regulatory mechanisms in lymph nodes utilize CTLA-4 on T cells to outcompete CD28 for B7 (CD80/86) costimulation on antigen-presenting cells. Anti-CTLA-4 (ipilimumab), Anti-PD-1 (pembrolizumab, nivolumab, cemiplimab), and Anti-PD-L1 (atezolizumab, durvalumab, avelumab) restore anti-tumor T-cell cytotoxicity across melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, Hodgkin lymphoma, and any tumor with Mismatch Repair Deficiency (dMMR) / High Microsatellite Instability (MSI-H). By breaking peripheral self-tolerance, they induce multi-organ autoimmune toxicities (colitis, pneumonitis, hepatitis, thyroiditis, hypophysitis, adrenalitis). Similarly, CD19 or BCMA Chimeric Antigen Receptor (CAR) T-cell therapies in refractory B-ALL, DLBCL, and multiple myeloma can trigger life-threatening Cytokine Release Syndrome (CRS: high fever, vasoplegic shock, capillary leak driven by IL-6) and ICANS (immune effector cell-associated neurotoxicity syndrome); CRS is treated specifically with the anti-IL-6 receptor antibody tocilizumab plus corticosteroids.

Every medical board candidate must master five mandatory chemoprotective antidote pairings: (1) Cyclophosphamide and Ifosfamide (nitrogen mustard alkylating agents activated by hepatic CYP2B6/3A4) generate the renally excreted toxic metabolite acrolein, which directly erodes the urothelium to cause hemorrhagic cystitis and long-term transitional cell bladder carcinoma; prevent with vigorous IV hydration and MESNA (2-mercaptoethanesulfonate), a sulfhydryl compound that binds and neutralizes acrolein inside the urinary bladder (ifosfamide also produces chloroacetaldehyde, causing encephalopathy treated with methylene blue). (2) High-dose Methotrexate (folate antimetabolite that competitively inhibits dihydrofolate reductase [DHFR] in S-phase) causes severe mucositis, myelosuppression, and crystalline nephrotoxicity; rescue normal host cells with Leucovorin (folinic acid / N⁵-formyl-THF), which bypasses blocked DHFR to replenish intracellular tetrahydrofolate pools (plus urinary alkalinization with NaHCO₃ and glucarpidase in renal failure). (3) Doxorubicin and Daunorubicin intercalate DNA, inhibit topoisomerase II, and complex with ferric iron (Fe³⁺) to generate hydroxyl free radicals that destroy cardiac myofibrils, causing irreversible dose-dependent dilated cardiomyopathy (cumulative dose >450–550 mg/m²); prevent with Dexrazoxane, an intracellular iron chelator and topoisomerase IIβ modulator. (4) Cisplatin (platinum cross-linking agent) causes severe proximal tubular necrosis (ATN with hypomagnesemia/hypokalemia) and high-frequency ototoxicity; prevent nephrotoxicity with aggressive IV 0.9% NaCl saline diuresis and Amifostine (an organic thiophosphate free-radical scavenger dephosphorylated selectively by normal tissue alkaline phosphatase). (5) 5-Fluorouracil (5-FU) is converted to FdUMP, which forms a covalent ternary complex with thymidylate synthase and folinic acid to induce "thymineless death"; here, co-administering leucovorin POTENTIATES (rather than rescues!) 5-FU efficacy by stabilizing its binding to thymidylate synthase (whereas 5-FU overdose or dihydropyrimidine dehydrogenase [DPD] deficiency is rescued with uridine triacetate).

Tumor Lysis Syndrome (TLS) is an oncologic emergency occurring 12–72 hours after initiating chemotherapy for high-turnover hematologic malignancies (Burkitt lymphoma, ALL, AML, CLL on venetoclax). Massive cell lysis releases intracellular ions and nucleic acids, producing the classic "3 Highs and 1 Low" electrolyte tetrad: Hyperkalemia (most rapidly fatal—cardiac arrhythmias!), Hyperphosphatemia, Hyperuricemia (uric acid crystals precipitate in acidic distal tubules causing acute kidney injury), and secondary Hypocalcemia (Ca²⁺ precipitates with PO₄³⁻ as calcium phosphate, causing tetany and seizures). Prophylaxis requires aggressive IV isotonic saline hydration plus allopurinol or febuxostat (xanthine oxidase inhibitors that prevent new uric acid formation); in high-risk patients or established TLS with uric acid >8 mg/dL, administer rasburicase (recombinant urate oxidase that directly enzymatic converts existing insoluble uric acid into water-soluble allantoin—strictly contraindicated in G6PD deficiency because the reaction generates H₂O₂, triggering severe hemolytic anemia and methemoglobinemia!).

Classic board organ-toxicity associations across cytotoxic chemotherapy include: Bleomycin and Busulfan cause dose-limiting pulmonary fibrosis (bleomycin complexes with Fe²⁺ and O₂ to cleave DNA in G₂ phase; because the lungs and skin lack bleomycin hydrolase, patients develop honeycombing interstitial pneumonitis and linear flagellate skin hyperpigmentation; high inspired FiO₂ precipitates acute respiratory failure). Vincristine (inhibits beta-tubulin polymerization in M-phase) causes dose-limiting stocking-glove peripheral and autonomic neuropathy (paralytic ileus, foot drop, loss of Achilles reflex) but spares the bone marrow, whereas Vinblastine ("blasts the marrow") causes severe myelosuppression. Taxanes (paclitaxel, docetaxel) hyperstabilize polymerized microtubules in M-phase (preventing mitotic spindle disassembly; "taxanes tie up tubules") and cause both neuropathy and myelosuppression. Irinotecan and Topotecan inhibit topoisomerase I (causing severe cholinergic early diarrhea and late secretory diarrhea with irinotecan, worse in UGT1A1*28 Gilbert syndrome homozygotes), whereas etoposide and teniposide inhibit topoisomerase II (causing alopecia and myelosuppression). Finally, asparaginase hydrolyzes extracellular L-asparagine required by ALL lymphoblasts, causing hypersensitivity, pancreatitis, and thrombosis via antithrombin III depletion.